Shares of Stemline Therapeutics Inc. (NASDAQ:STML) were up 3.3% on Monday . The company traded as high as $7.32 and last traded at $7.30, with a volume of 81,001 shares. The stock had previously closed at $7.07.

A number of analysts have recently weighed in on STML shares. Jefferies Group restated a “buy” rating and issued a $23.00 price objective on shares of Stemline Therapeutics in a research note on Monday, June 6th. Roth Capital reiterated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Wednesday, July 6th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, June 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.56.

The company’s market capitalization is $130.15 million. The company’s 50-day moving average is $7.37 and its 200-day moving average is $5.73.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.08. The business had revenue of $205.65 million for the quarter, compared to the consensus estimate of $121.43 million. On average, equities analysts predict that Stemline Therapeutics Inc. will post ($2.23) earnings per share for the current year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC raised its stake in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned 0.91% of Stemline Therapeutics worth $1,004,000 at the end of the most recent quarter.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.